Hyperlipidemias: Clinical Trials

1653 completed, 236 unknown, 138 recruiting, 113 terminated. 700 Not applicable, 492 Phase 3, 343 Phase 2, 246 Phase 1, 244 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	700	Completed 475, Unknown 95, Recruiting 51, Active not recruiting 22, Not yet recruiting 19, Terminated 18, Withdrawn 10, Enrolling by invitation 9, Suspended 1
Phase 3	492	Completed 385, Terminated 34, Unknown 22, Active not recruiting 16, Recruiting 16, Not yet recruiting 8, Withdrawn 8, Enrolling by invitation 3
Phase 2	343	Completed 260, Terminated 23, Unknown 19, Recruiting 17, Not yet recruiting 10, Active not recruiting 7, Withdrawn 5, Enrolling by invitation 1, Suspended 1
Phase 1	246	Completed 196, Terminated 13, Unknown 12, Recruiting 10, Not yet recruiting 8, Withdrawn 4, Active not recruiting 2, Enrolling by invitation 1
Phase 4	244	Completed 168, Unknown 40, Terminated 13, Withdrawn 8, Not yet recruiting 6, Recruiting 5, Active not recruiting 3, Suspended 1
Early Phase 1	28	Completed 14, Recruiting 7, Not yet recruiting 3, Active not recruiting 1, Enrolling by invitation 1, Terminated 1, Unknown 1

Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Coronary Artery Calcium (CAC) Testing in Primary Care Our Practice Advisory (OPA) - ASCVD, ASCVD Management	Not applicable	Not yet recruiting	Weill Medical College of Cornell University	20	2027-02-01	2026-10-15
PCSK9 Inhibitors in Hyperlipidemia and Atherosclerosis Hyperlipidemia, Atherosclerotic Cardiovascular Disease (ASCVD)		Not yet recruiting	Fundación Santa Fe de Bogota	100	2027-02-01	2026-10-02
A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical Atheroma Evolocumab, Routine Lipid Management, Autoinjector - Coronary Artery Disease, Hypercholesterolemia	Phase 4	Not yet recruiting	Amgen	308	2027-01-31	2026-09-21
RCT for the Chinese Medicine in Treating Hypercholesterolemia Dachaihu Decoction combined Erzhiwan with variation, Placebo granules - Hypercholesterolemia	Phase 2	Not yet recruiting	Chinese University of Hong Kong	70	2027-01-01	2026-07-30
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia Hypercholesterolaemia, Familial Hypercholesterolaemia		Not yet recruiting	Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)	2500	2027-01-01	2026-11-03
Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk Lipid-Lowering Therapy in Routine Clinical Practice - Dyslipidemias, Hypercholesterolemia		Not yet recruiting	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	1600	2027-01-01	2026-11-12
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolemia	Phase 3	Not yet recruiting	AstraZeneca	204	2026-12-21	2026-11-12
Study of YKYY032 Injection in Adults With Hyperlipoproteinemia (a) YKYY032 group, YKYY032 Placebo group - Hyperlipoproteinemia (a)	Phase 2	Not yet recruiting	Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.	192	2026-11-20	2026-11-03
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia High fat liquid shake - Lipid Metabolism Disorders	Not applicable	Not yet recruiting	National Heart, Lung, and Blood Institute (NHLBI)	48	2026-11-17	2026-11-12
Penn Family Screening for Familial Hypercholesterolemia (NHLBI R33) Trial 3 Cascade Screening - Familial Hypercholesterolemia	Not applicable	Not yet recruiting	Northwestern University	110	2026-11-15	2026-11-05
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) Drug: EDIT-401, Placebo - Heterozygous Familial Hypercholesterolemia (HeFH)	Phase 1 / Phase 2	Not yet recruiting	Editas Medicine, Inc.	56	2026-11-01	2026-10-26
A Phase 1 Study of VELA-101 in Adult Participants VELA-101, Placebo - Healthy Participants, Hyperlipidemia	Phase 1	Not yet recruiting	Ursa Medicines	60	2026-11-01	2026-10-15
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease Dose adjustment of statins, no dose adjustment - Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Stroke (CVA) or TIA	Phase 4	Not yet recruiting	Rehman Medical Institute - RMI	178	2026-11-01	2026-11-05
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia inclisiran, SOC - Acute Coronary Syndrome	Phase 4	Not yet recruiting	Novartis Pharmaceuticals	300	2026-10-31	2026-10-30
Team-Based Shared Decision-Making Program in Cardiovascular-Kidney-Metabolic Health (Healthy Heart - CKM) Team-based shared decision-making - Hypertension (HTN), Diabetes (DM)	Early Phase 1	Not yet recruiting	Johns Hopkins University	94	2026-10-30	2026-10-19
Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk	Phase 3	Not yet recruiting	Uppsala University	250	2026-10-30	2026-09-08
Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP Cascade testing, Standard of Care - Familial Hypercholesterolemia	Not applicable	Not yet recruiting	Mayo Clinic	480	2026-10-20	2026-09-18
Metabolic Effects of an Ophiocordyceps Sinensis- and CoQ10-Based Formulation in Mild-to-Moderate Hypercholesterolemia CORDICOL, Placebo - Hypercholesterolemia, Lipid Metabolism Disorders	Not applicable	Not yet recruiting	noiVita Srls	140	2026-10-19	2026-10-08
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT) Antiphospholipid (aPL)-Positive, Rheumatic Arthritis		Not yet recruiting	Axiom Bioregistry	5000	2026-10-18	2026-10-23
A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia	Phase 3	Recruiting	Merck Sharp & Dohme LLC	150	2026-10-15	2026-11-02

Showing 20 of 2340. Sign in to see all of them.

Narrower conditions

Hypercholesterolemia (1135)  ·  Hypertension (352)  ·  Hypertriglyceridemia (316)  ·  Cardiovascular Diseases (252)  ·  Diabetes Mellitus (239)  ·  Dyslipidemias (230)  ·  Hyperlipoproteinemia Type II (227)  ·  Obesity (190)  ·  Atherosclerosis (131)  ·  Diabetes Mellitus, Type 2 (111)  ·  Metabolic Syndrome (102)  ·  Coronary Disease (79)  ·  Coronary Artery Disease (76)  ·  Insulin Resistance (73)

Broader conditions

Nutritional and Metabolic Diseases (2334)  ·  Metabolic Diseases (2295)  ·  Lipid Metabolism Disorders (2290)  ·  Dyslipidemias (2110)  ·  Vascular Diseases (599)  ·  Cardiovascular Diseases (493)  ·  Glucose Metabolism Disorders (459)  ·  Pathological Conditions, Signs and Symptoms (372)  ·  Endocrine System Diseases (355)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (343)  ·  Genetic Diseases, Inborn (326)  ·  Metabolism, Inborn Errors (322)  ·  Lipid Metabolism, Inborn Errors (314)  ·  Hyperlipoproteinemias (299)

Interventions

Atorvastatin (205)  ·  Ezetimibe (176)  ·  Rosuvastatin Calcium (136)  ·  Simvastatin (107)  ·  evolocumab (59)  ·  alirocumab (53)  ·  Fenofibrate (52)  ·  Pravastatin (34)  ·  Hydroxymethylglutaryl-CoA Reductase Inhibitors (33)  ·  Omacor (33)  ·  ALN-PCS (30)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (29)  ·  pitavastatin (29)  ·  Niacin (28)  ·  Ezetimibe, Simvastatin Drug Combination (25)

Sponsors

Organon and Co (93)  ·  AstraZeneca (90)  ·  Amgen (42)  ·  National Heart, Lung, and Blood Institute (NHLBI) (41)  ·  Novartis Pharmaceuticals (41)  ·  Merck Sharp & Dohme LLC (40)  ·  Pfizer (40)  ·  Sanofi (37)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (26)  ·  Takeda (23)  ·  Regeneron Pharmaceuticals (22)  ·  Esperion Therapeutics, Inc. (18)  ·  University of Pennsylvania (17)  ·  Arrowhead Pharmaceuticals (14)  ·  Kastle Therapeutics, LLC (13)

Countries

United States (826)  ·  Canada (281)  ·  China (185)  ·  South Korea (161)  ·  Netherlands (148)  ·  Germany (140)  ·  Italy (127)  ·  United Kingdom (127)  ·  Spain (121)  ·  France (118)  ·  Australia (88)  ·  South Africa (82)  ·  Czechia (81)  ·  Japan (79)  ·  Denmark (78)

Top investigators

Russell Esterline (8)  ·  Ron Haberman, MD (7)  ·  Robert D Shamburek, M.D. (6)  ·  David JA Jenkins, MD, PhD, DSc (5)  ·  Evan A Stein, MD PhD (5)

Results publications

PMID 30183102, PMID 37994400, PMID 21518985, PMID 33078867, PMID 27777279, PMID 34298554, PMID 38018702, PMID 28181260, PMID 40587053, PMID 28304227, PMID 28964736, PMID 29685591, PMID 33990512, PMID 35277540, PMID 25614280, PMID 27578134, PMID 28324110, PMID 32609313, PMID 34677608, PMID 35916348, PMID 37565307, PMID 38063346, PMID 22301925, PMID 26872608, PMID 28391886, PMID 29037448, PMID 31194872, PMID 34617591, PMID 36520008, PMID 37658997, PMID 38757725, PMID 41604274, PMID 10205010, PMID 17407645, PMID 19029469, PMID 20573639, PMID 20663203, PMID 20707601, PMID 21401833, PMID 21613319, PMID 22087637, PMID 22500948, PMID 23325450, PMID 24014831, PMID 24528690, PMID 25060413, PMID 25091629, PMID 25269777, PMID 25431239, PMID 25456098

NIH funding

2015 (17), 2005 (12), 2023 (10), 2025 (9), 2017 (8), 2016 (7), 2014 (5), 2018 (5), 2019 (3), OT2HL158287 (3), 2004 (2), 2008 (2), K23GM100372 (2), K23HL169929 (2), P01HS021141 (2)